KURA

Kura Oncology, Inc. (KURA) | Rumor.io

Kura Oncology

KURA

Attention (50-day avg)0%

Attention rank (50-day avg)#878

Bullish sentiment (50-day avg)97%

Price to earnings ratio-3.35

Market capitalization943.9M

Earnings per share-3.32

Dividend yield (TTM)—

Revenue (annual)67.5M

Net income (annual)-278.7M

Social

What share of all stock conversation is about KURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 9

Kura Oncology, Inc. (KURA) has secured $50 million in financing led by BVF Partners and other investors, with a significant portion of the capital coming from sophisticated biotech/diabetes investors.
The company has spun off Caspian Therapeutics, which has attracted an equity investment from Eli Lilly and Company, establishing a direct financial relationship between the two companies.
Kura Oncology's management team has implemented a brilliant structural play by creating a high-upside option for the company's shareholders, with the potential to add double-digit dollars to the share price if the diabetes biology translates in human trials.

Generated by AI

Sentiment

Of the messages about KURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +18.18	90.28% -9.11	91.81% +16.32
Bearish	0%	0% -18.18	9.72% +9.11	8.19% -16.32

Bullish· Apr 17

Kura Oncology's FIT-001 treatment drug has received excellent trial data, making its future look extremely promising.
The company has a strong cash position relative to its market capitalization, alleviating concerns about future cash flow.
With a Strong Buy consensus rating and an average price target of $25-$28, Kura Oncology has significant upside potential, with a 218.57% implied price increase.

Bearish· Nov 13

$KURA's recent performance is attributed to its red candle and a dump that was anticipated by some investors.
The company's boxed warning label on its drug is a significant concern, as it may deter patients from using the medication, potentially leading to a decrease in sales.
Some investors believe that $KURA's poor performance is a result of its bad licensing deal and lower efficacy compared to its competitors, such as SNDX.

Generated by AI

Topics

Of the messages about KURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	91.62%	67.6%
Technical Analysis	—	—	7.33%	13.5%
Analysts	—	—	1.05%	10.58%
Earnings	—	—	0%	2.07%
Controversies	—	—	0%	0.31%
Macro	—	—	0%	5.94%

Nov 14

Kura Oncology's zifto (Komzifti) has been FDA approved for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
The therapy's approval comes with a favorable safety profile, including no Black Box Warning for QTc prolongation, and a higher price point of $48.5k WAC.
Kura Oncology and Kyowa Kirin are fully prepared to launch Komzifti, with Kura CEO Troy Wilson noting its "best-in-class profile" and potential as the menin inhibitor of choice within its approved indication.

Generated by AI

Community

Of the messages about KURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	89.04%	92.2%	56.64%
Newcomers	66.67%	10.96%	7.8%	43.36%

Regulars· Aug 25

The CEO of Kura Oncology, Troy Wilson, has been actively buying shares, with his latest purchase of $1.24 million worth of stock.
Kura Oncology's AML drug, KOMZIFTI, has continued to show momentum, with a majority share of new patient starts in the R/R NPM1-mutated AML menin inhibitor class.
The company's revenue has increased 57% sequentially to $9.1 million, with new patient starts increasing 35% to approximately 115 and total prescriptions increasing 59% to more than 250.

Newcomers· Aug 25

Newcomers are noticing a strong breakout in $KURA, with the stock reclaiming its $12.50 resistance and potentially targeting $14.50–16.00.
Many are discussing the recent open-market buys by Kura Oncology's CEO, Wilson Troy Edward, with some interpreting this as a positive sign for the company.
The Kyowa Kirin relationship is being highlighted as a significant factor in $KURA's potential, with a $330M upfront commitment and potentially $1B+ in additional economics, providing capital, global infrastructure, and external validation.

Generated by AI

News

Also Discussed

Investors talking about KURA also mention

#	Name	Attention
1	Syndax Pharmaceuticals, Inc.SNDX	0%+0
2	DAWN - Day One Biopharmaceuticals, Inc.	——
3	Cullinan Therapeutics Inc.CGEM	0%new
4	Arvinas, Inc.ARVN	0%+0
5	IDEAYA Biosciences Inc.IDYA	0%-0.01
6	Sutro Biopharma Inc.STRO	0%new
7	SWTX - SpringWorks Therapeutics, Inc.	——
8	Bicycle Therapeutics plc - ADRBCYC	0%0
9	MRTX - Mirati Therapeutics, Inc.	——
10	Mineralys Therapeutics, Inc.MLYS	0%+0

Kura Oncology, Inc.

Healthcare
Biotechnology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.

Website

Location

4930 Directors Place

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about KURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 9

Kura Oncology, Inc. (KURA) has secured $50 million in financing led by BVF Partners and other investors, with a significant portion of the capital coming from sophisticated biotech/diabetes investors.
The company has spun off Caspian Therapeutics, which has attracted an equity investment from Eli Lilly and Company, establishing a direct financial relationship between the two companies.
Kura Oncology's management team has implemented a brilliant structural play by creating a high-upside option for the company's shareholders, with the potential to add double-digit dollars to the share price if the diabetes biology translates in human trials.

Generated by AI

Sentiment

Of the messages about KURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +18.18	90.28% -9.11	91.81% +16.32
Bearish	0%	0% -18.18	9.72% +9.11	8.19% -16.32

Bullish· Apr 17

Kura Oncology's FIT-001 treatment drug has received excellent trial data, making its future look extremely promising.
The company has a strong cash position relative to its market capitalization, alleviating concerns about future cash flow.
With a Strong Buy consensus rating and an average price target of $25-$28, Kura Oncology has significant upside potential, with a 218.57% implied price increase.

Bearish· Nov 13

$KURA's recent performance is attributed to its red candle and a dump that was anticipated by some investors.
The company's boxed warning label on its drug is a significant concern, as it may deter patients from using the medication, potentially leading to a decrease in sales.
Some investors believe that $KURA's poor performance is a result of its bad licensing deal and lower efficacy compared to its competitors, such as SNDX.

Generated by AI

Topics

Of the messages about KURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	91.62%	67.6%
Technical Analysis	—	—	7.33%	13.5%
Analysts	—	—	1.05%	10.58%
Earnings	—	—	0%	2.07%
Controversies	—	—	0%	0.31%
Macro	—	—	0%	5.94%

Nov 14

Kura Oncology's zifto (Komzifti) has been FDA approved for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
The therapy's approval comes with a favorable safety profile, including no Black Box Warning for QTc prolongation, and a higher price point of $48.5k WAC.
Kura Oncology and Kyowa Kirin are fully prepared to launch Komzifti, with Kura CEO Troy Wilson noting its "best-in-class profile" and potential as the menin inhibitor of choice within its approved indication.

Generated by AI

Community

Of the messages about KURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	89.04%	92.2%	56.64%
Newcomers	66.67%	10.96%	7.8%	43.36%

Regulars· Aug 25

The CEO of Kura Oncology, Troy Wilson, has been actively buying shares, with his latest purchase of $1.24 million worth of stock.
Kura Oncology's AML drug, KOMZIFTI, has continued to show momentum, with a majority share of new patient starts in the R/R NPM1-mutated AML menin inhibitor class.
The company's revenue has increased 57% sequentially to $9.1 million, with new patient starts increasing 35% to approximately 115 and total prescriptions increasing 59% to more than 250.

Newcomers· Aug 25

Newcomers are noticing a strong breakout in $KURA, with the stock reclaiming its $12.50 resistance and potentially targeting $14.50–16.00.
Many are discussing the recent open-market buys by Kura Oncology's CEO, Wilson Troy Edward, with some interpreting this as a positive sign for the company.
The Kyowa Kirin relationship is being highlighted as a significant factor in $KURA's potential, with a $330M upfront commitment and potentially $1B+ in additional economics, providing capital, global infrastructure, and external validation.

Generated by AI

Kura Oncology

Social

Sep 9

Bullish· Apr 17

Bearish· Nov 13

Nov 14

Regulars· Aug 25

Newcomers· Aug 25

Kura Oncology CCO Brian Powl sells over $345k in company stock

Kura Oncology SVP sells $48,360 of stock

Kura Oncology chief legal officer sells $88,618 in shares

Kura Oncology COO Kathleen Ford sells $111,930 in company stock

Kura Oncology CMO Mollie Leoni reports $440,236 stock sales

Kura Oncology Q2 2026 Earnings Call Transcript

Also Discussed

Kura Oncology, Inc.

Company Information

Location

Kura Oncology CCO Brian Powl sells over $345k in company stock

Kura Oncology SVP sells $48,360 of stock

Kura Oncology chief legal officer sells $88,618 in shares

Kura Oncology COO Kathleen Ford sells $111,930 in company stock

Kura Oncology CMO Mollie Leoni reports $440,236 stock sales

Kura Oncology Q2 2026 Earnings Call Transcript

Also Discussed

Social

Sep 9

Bullish· Apr 17

Bearish· Nov 13

Nov 14

Regulars· Aug 25

Newcomers· Aug 25